Mirum Pharmaceuticals/MIRM

$23.81

1.01%
-
1D1W1MYTD1YMAX

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development and commercialization of therapies for debilitating rare and orphan diseases. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. It is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.

Ticker

MIRM

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Michael Grey

Employees

264

Headquarters

Foster city, United States

MIRM Metrics

BasicAdvanced
$1.12B
Market cap
-
P/E ratio
-$4.08
EPS
1.15
Beta
-
Dividend rate
$1.12B
1.14752
$35.56
$23.76
522.12K
4.451
4.195
123.224
123.224
-79.67%
-32.7%
-83.65%
-38.55%
6.015
4.481
141.85%
-1.64%

What the Analysts think about MIRM

Analyst Ratings

Majority rating from 11 analysts.
Buy

Price Targets

Average projection from 11 analysts.
105.42% upside
High $72.00
Low $33.00
$23.81
Current price
$48.91
Average price target

MIRM Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-51.22% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$69.5M
45.7%
Net income
$-35.6M
51.49%
Profit margin
-51.22%
3.98%

MIRM Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 171.6%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.80
-$1.94
-$0.57
-$0.66
-
Expected
-$0.94
-$0.80
-$0.63
-$0.24
-$0.48
Surprise
-14.74%
143.9%
-9.3%
171.6%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Mirum Pharmaceuticals stock?

Mirum Pharmaceuticals (MIRM) has a market cap of $1.12B as of April 21, 2024.

What is the P/E ratio for Mirum Pharmaceuticals stock?

The price to earnings (P/E) ratio for Mirum Pharmaceuticals (MIRM) stock is 0 as of April 21, 2024.

Does Mirum Pharmaceuticals stock pay dividends?

No, Mirum Pharmaceuticals (MIRM) stock does not pay dividends to its shareholders as of April 21, 2024.

When is the next Mirum Pharmaceuticals dividend payment date?

Mirum Pharmaceuticals (MIRM) stock does not pay dividends to its shareholders.

What is the beta indicator for Mirum Pharmaceuticals?

Mirum Pharmaceuticals (MIRM) has a beta rating of 1.15. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Mirum Pharmaceuticals stock price target?

The target price for Mirum Pharmaceuticals (MIRM) stock is $48.91, which is 105.42% above the current price of $23.81. This is an average based on projections from 11 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Mirum Pharmaceuticals stock

Buy or sell Mirum Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing